[CrossRef] 155. da Cunha Santos, G.; Shepherd, F.A.; Tsao, M.S. EGFR Mutations and Lung Cancer. Annu. Rev. Pathol. 2011 ,6, 49–69. [CrossRef] 156. Li, F.; Deng, L.; Jackson, K.R.; Talukder, A.H.; Katailiha, A.S.; Bradley, S.D.; Zou, Q.; Chen, C.; Huo, C.; Chiu, Y.; et al. Neoantigen Vaccination Induces Clinical and Immunologic Responses in Non-Small Cell Lung Cancer Patients Harboring EGFR Mutations. J. Immunother. Cancer 2021 ,9, e002531. [CrossRef] [PubMed] 157. Kobayashi, Y.; Mitsudomi, T. Not All Epidermal Growth Factor Receptor Mutations in Lung Cancer Are Created Equal: Perspectives for Individualized Treatment Strategy. Cancer Sci. 2016 ,107, 1179–1186. [CrossRef] Vaccines 2024 ,12, 717 24 of 24 158. Gonz ález-Galarza, F.F.; Takeshita, L.Y.C.; Santos, E.J.M.; Kempson, F.; Maia, M.H.T.; da Silva, A.L.S.; Teles e Silva, A.L.; Ghattaoraya, G.S.; Alfirevic, A.; Jones, A.R.; et al. Allele Frequency Net 2015 Update: New Features for HLA Epitopes, KIR and Disease and HLA Adverse Drug Reaction Associations. Nucleic Acids Res. 2015 ,43, D784–D788. [CrossRef] 159. Bailey, M.H.; Tokheim, C.; Porta-Pardo, E.; Sengupta, S.; Bertrand, D.; Weerasinghe, A.; Colaprico, A.; Wendl, M.C.; Kim, J.; Reardon, B.; et al. Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell2018 ,173, 371–385.e18. [CrossRef] [PubMed] 160. Chandran, S.S.; Ma, J.; Klatt, M.G.; Dündar, F.; Bandlamudi, C.; Razavi, P .; Wen, H.Y.; Weigelt, B.; Zumbo, P .; Fu, S.N.; et al. Immunogenicity and Therapeutic Targeting of a Public Neoantigen Derived from Mutated PIK3CA. Nat. Med. 2022 ,28, 946–957. [CrossRef] 161. Mota, I.; Patrucco, E.; Mastini, C.; Mahadevan, N.R.; Thai, T.C.; Bergaggio, E.; Cheong, T.-C.; Leonardi, G.; Karaca-Atabay, E.; Campisi, M.; et al. ALK Peptide Vaccination Restores the Immunogenicity of ALK-Rearranged Non-Small Cell Lung Cancer. Nat. Cancer 2023 ,4, 1016–1035. [CrossRef] 162. Melero, I.; Gaudernack, G.; Gerritsen, W.; Huber, C.; Parmiani, G.; Scholl, S.; Thatcher, N.; Wagstaff, J.; Zielinski, C.; Faulkner, I.; et al. Therapeutic Vaccines for Cancer: An Overview of Clinical Trials. Nat. Rev. Clin. Oncol. 2014 ,11, 509–524. [CrossRef] 163. Mellman, I.; Coukos, G.; Dranoff, G. Cancer Immunotherapy Comes of Age. Nature 2011 ,480, 480–489. [CrossRef] 164. Kantoff, P .W.; Higano, C.S.; Shore, N.D.; Berger, E.R.; Small, E.J.; Penson, D.F.; Redfern, C.H.; Ferrari, A.C.; Dreicer, R.; Sims, R.B.; et al. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. N. Engl. J. Med. 2010 ,363, 411–422. [CrossRef] [PubMed] 165. Adot évi, O.; Vernerey, D.; Jacoulet, P .; Meurisse, A.; Laheurte, C.; Almotlak, H.; Jacquin, M.; Kaulek, V .; Boullerot, L.; Malfroy, M.; et al. Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide–Based Vaccine in Patients With Refractory Advanced Non–Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study. J. Clin. Oncol. 2023 ,41, 373–384. [CrossRef] 166. Kjeldsen, J.W.; Lorentzen, C.L.; Martinenaite, E.; Ellebaek, E.; Donia, M.; Holmstroem, R.B.; Klausen, T.W.; Madsen, C.O.; Ahmed, S.M.; Weis-Banke, S.E.; et al. A Phase 1/2 Trial of an Immune-Modulatory Vaccine against IDO/PD-L1 in Combination with Nivolumab in Metastatic Melanoma. Nat. Med. 2021 ,27, 2212–2223. [CrossRef] 167. Hanahan, D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022 ,12, 31–46. [CrossRef] 168. Hanahan, D.; Weinberg, R.A. Hallmarks of Cancer: The next Generation. Cell2011 ,144, 646–674. [CrossRef] [PubMed] 169. de Visser, K.E.; Joyce, J.A. The Evolving Tumor Microenvironment: From Cancer Initiation to Metastatic Outgrowth. Cancer Cell 2023 ,41, 374–403. [CrossRef] [PubMed] 170. Bejarano, L.; Jord ¯ao, M.J.C.; Joyce, J.A. Therapeutic Targeting of the Tumor Microenvironment. Cancer Discov. 2021 ,11, 933–959. [CrossRef] 171. Mantovani, A.; Allavena, P .; Marchesi, F.; Garlanda, C. Macrophages as Tools and Targets in Cancer Therapy. Nat. Rev. Drug Discov. 2022 ,21, 799–820. [CrossRef] 172. Chen, Y.; McAndrews, K.M.; Kalluri, R. Clinical and Therapeutic Relevance of Cancer-Associated Fibroblasts. Nat. Rev. Clin. Oncol. 2021 ,18, 792–804. [CrossRef] 173. Luo, H.; Xia, X.; Huang, L.-B.; An, H.; Cao, M.; Kim, G.D.; Chen, H.-N.; Zhang, W.-H.; Shu, Y.; Kong, X.; et al. Pan-Cancer Single-Cell Analysis Reveals the Heterogeneity and Plasticity of Cancer-Associated Fibroblasts in the Tumor Microenvironment. Nat.